After closely following the company's partnership language over the past year, I was of the opinion it would be P first, which makes total sense, but then 2 things happened.

1) P enrollment took longer than expected.
2) OM enrollment increased significantally

Based on these 2 events, my bet is on B as well. B has been proven safe from the ABSSSI trials; B has been shown to be effective in the UP open label trial; finally, the placebo controlled OM will show it will hold up in double blind, placebo controlled trials

Either BP gives Leo a great deal for B, or he will wait a month or two and land a P deal...